Full-Time
Senior Translational Science Lead
Posted on 10/31/2025
PathAI
201-500 employees
AI-powered pathology platform for diagnostics
Compensation Overview
$127.5k - $195.5k/yr
Boston, MA, USA
In Person
 Biology & Biotech (3) |
|---|
| , , |
- 5+ years of experience in biotech, pharmaceutical or medical device industries.
- Advanced degree in life sciences or biomedical engineering-related disciplines required, PhD preferred.
- Ability to process quantitative datasets and broad comfort with statistics.
- Intellectual curiosity and the ability to learn quickly in a complex space.
- Strong organizational skills and experience managing project timelines
- Responsible for the scientific and strategic development of company projects.
- Drive and uphold rigorous scientific standards, bringing consistency to the analyses you encounter and ensuring our discoveries are adequately reviewed.
- Apply cutting edge approaches towards understanding disease biology to improve precision medicine and biomarker development.
- Solve interesting problems with machine learning and data science.
- Oversee day-to-day technical developments and manage relationships with internal and external stakeholders
- Collaborate across a range of groups - product, design, engineering front-end, machine learning, business operations, and infrastructure teams.
- Recommend new features for internal and external users, and improve existing ones to enhance the user experience.
- Drive the prioritization of our platform development, considering the team and our future roadmap.
- Mentor, learn, and share knowledge with others along the way.
- None specified in the job posting
PathAI builds an AI-powered pathology platform that helps healthcare providers, research institutions, and pharmaceutical companies improve cancer diagnosis and treatment. Its tools analyze pathology images and other data to support pathologists, offering quantitative analysis, biomarkers, and diagnostic reports to increase accuracy and guide treatment decisions. The company differentiates itself by focusing on real-world clinical deployment and partnerships across providers, researchers, and pharma, combining diagnostic services with licensing and services to scale adoption. PathAI aims to improve patient outcomes by making pathology-based diagnoses more accurate and actionable, advancing personalized medicine.
Company Size
201-500
Company Stage
Acquired
Total Funding
$1.1B
Headquarters
Boston, Massachusetts
Founded
2016
Simplify's Take
What believers are saying
- Roche acquires PathAI for $750M upfront plus $300M milestones, closing H2 2026.
- Labcorp deploys AISight Dx across US labs, building on 2019 investment.
- Partnerships with MedStar Health and University Hospital Zurich deploy AI tools in 2026.
What critics are saying
- FTC antitrust scrutiny blocks Roche acquisition by mid-2027, stranding PathAI.
- Quest Diagnostics launches competing AI tools using 2019 investment, eroding biopharma share by 2028.
- Brazil SUS rejects AISight for primary diagnosis by August 2026, halting expansion.
What makes PathAI unique
- AISight Dx is FDA-cleared for primary diagnosis in US and CE-IVD marked in EEA, UK, Switzerland.
- PathAI leverages 32.5 million annotations from 450 pathologists to train AI models.
- 90% of top 15 biopharma companies use PathAI for biomarker discovery in oncology, NASH, IBD.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive medical, dental, and vision insurance
Retirement plan options
Paid parental leave
Health & wellness benefits
Flexible work options
Generous paid time off
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%PathAI and MedStar Health announce partnership to deploy the AISight(R) Dx Digital Pathology Platform and advanced AI applications. April 07, 2026 09:00 ET | Source: PathAI BOSTON and COLUMBIA, Md., April 07, 2026 (GLOBE NEWSWIRE) - PathAI, a leading provider of AI-powered pathology solutions, and MedStar Health, a leading health system headquartered in Columbia, Maryland, today announced a multi-year strategic collaboration to deploy PathAI's AISight(R) Dx[1] Digital Pathology Platform and various AI algorithm products across the multi-site network. AISight(R) Dx is PathAI's cloud native digital pathology image management system designed to support laboratory workflows, clinical operations and research initiatives. It combines enterprise scale slide management, viewing, and collaboration with seamless AI integration to drive enhanced efficiency and improve speed and consistency. MedStar Health will also deploy algorithms, including ArtifactDetect and TumorDetect[2], to further transform pathology workflows across their network of laboratories supporting over 40 pathologists. "At MedStar Health, we are focused on scaling high-quality care across a large and growing health system, including a rapidly expanding outreach business, and digital pathology is a critical enabler of that mission," Moira Larsen, MD, Physician Executive Director of MedStar Medical Group Pathology at MedStar Health. "By deploying AISight(R) Dx and advanced AI applications, we are modernizing our pathology infrastructure in a way that makes us more connected, more efficient, and better positioned to bring innovative diagnostics into everyday practice. This collaboration allows MedStar to lead in the adoption of digital and AI technology while maintaining our focus on delivering exceptional outcomes for the patients and communities we serve." The deployment of AISight Dx at scale builds upon MedStar Health's participation in PathAI's Early Access Program as well as prior research initiatives, including an independent validation of PathAI's AIM-HER2 Breast algorithm. The partnership lays the groundwork for further collaboration as part of PathAI's Precision Pathology Network, allowing MedStar Health to pursue joint research initiatives, generate real-world multimodal data, support clinical trials and biopharma partnerships, and co-develop advanced AI diagnostics. "Digital pathology and AI are transforming how health systems generate insight and scale impact," said Nick Brown, Chief Growth Officer of PathAI. "Through our collaboration with MedStar Health, we're building a modern digital infrastructure that will accelerate innovation and future-proof MedStar's pathology growth." 1 AISight(R) Dx is FDA-cleared for primary diagnosis in the US and is CE-IVD-marked for primary diagnosis in the EEA, UK, and Switzerland. 2 ArtifactDetect is a workflow tool on AISight Dx. TumorDetect is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit www.pathai.com. About MedStar Health MedStar Health is a not-for-profit health system dedicated to caring for people in Maryland and the Washington, D.C., region, while advancing the practice of medicine through education, innovation and research. MedStar's 30,000 associates, 6,000 affiliated physicians, 10 hospitals, ambulatory care and urgent care centers, and the MedStar Health Research Institute are recognized regionally and nationally for excellence in medical care. As the medical education and clinical partner of Georgetown University, MedStar trains more than 1,100 medical residents annually. MedStar Health's patient-first philosophy combines care, compassion and clinical excellence with an emphasis on customer service. For more information, please visit https://www.medstarhealth.org/.
PathAI, a Boston-based AI-powered pathology solutions provider, has received US FDA Breakthrough Device Designation for PathAssist Derm, designed to analyse digital pathology images of skin lesions and assist pathologists in their review. The designation addresses critical challenges in dermatopathology, where skin cancer is the most commonly diagnosed cancer in the United States. Studies show inter-observer concordance and accuracy for diagnostically challenging melanocytic lesions fall below 50% compared to consensus reference diagnoses. PathAssist Derm aims to help pathologists manage rising caseloads whilst maintaining diagnostic rigour. This marks PathAI's latest regulatory achievement, following recent 510(k) clearance for its AISight Dx Image Management System and EMA and FDA qualification of AIM-MASH AI Assist as the first AI-powered pathology Drug Development Tool.
Labcorp has expanded its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology enables pathologists to view and manage slides digitally whilst using AI to support diagnostic processes. The platform will facilitate fully digital workflows for case management, slide review, collaboration and annotation. It integrates AI-powered image analysis, secure storage and system connectivity to deliver faster turnaround times and improved efficiency. The expansion builds on Labcorp's 2019 strategic investment in PathAI. The company will also incorporate digital pathology workflows to support its precision medicine products. Labcorp operates nearly 71,000 employees serving clients in approximately 100 countries.
PathAI and University Hospital Zurich announce collaboration to deploy AISight(R) Dx and AIM-TumorCellularity for routine Molecular Pathology workflows. January 08, 2026 03:00 ET | Source: PathAI BOSTON, Mass. and ZURICH, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) - PathAI, a global leader in AI-powered pathology, today announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight(R) Dx[1], PathAI's CE-IVD digital pathology platform, together with AIM-TumorCellularity (AIM-TC)[2] to support tumor cell content (TCC) quantification in routine molecular workflows. The collaboration marks one of the first implementations of an AI-based tool in daily pathology operation in Switzerland. USZ will use AIM-TC to support the routine assessment of TCC prior to next-generation sequencing (NGS), which requires a minimum amount of tumor cells in a sample to allow NGS to accurately detect actionable biomarkers that guide therapy decisions for the patient. The PathAI algorithm provides a stable, quantitative TCC estimate to increase consistency and confidence in the quality of samples selected for molecular diagnostics. Human pathologists' TCC assessment is time-consuming, resource intensive, and subject to limited availability, which can delay the initiation of molecular testing until a pathologist is able to review the case. Manual TCC assessment is also plagued by low accuracy and reproducibility; inaccurate TCC quantification can lead to failed sequencing and destruction of tissue, a significant challenge for patients with limited tissue available for further testing. A study entitled "The estimation of tumor cell percentage for molecular testing by pathologists is not accurate" found that pathologists overestimated tumor cell percentage in 38% of cases, possibly causing false negative results[3]. USZ selected PathAI following what is considered the most comprehensive analytical evaluation to date of an AI-based TCC algorithm. Preliminary results from this evaluation have been presented at the 2024 European Congress of Pathology, the 2025 European Congress of Digital Pathology, and the 2025 Swiss Society of Pathology Annual Meeting, with a detailed scientific publication forthcoming. "USZ's thorough and scientifically rigorous evaluation of AIM-TC reflects exactly the spirit of evidence-driven innovation we strive for at PathAI," said Eric Walk, MD, Chief Medical Officer of PathAI. "We are proud that AIM-TC meets the exceptionally high analytical standards of USZ, and we look forward to advancing future projects together." "AIM-TC showed strong and reliable performance throughout our evaluation, with accuracy that held up even in difficult real-world samples," said Professor Holger Moch, Director of the Department of Pathology and Molecular Pathology at USZ. PD Dr. Bettina Sobottka, Director of the Department's Division of Molecular Pathology, added, "We were impressed by the consistency of the results and by PathAI's scientific rigor, which gave us confidence in bringing this technology into routine molecular diagnostics and in choosing PathAI as a partner for the years to come." About PathAI PathAI is a leading provider of AI-powered pathology solutions that aim to improve the accuracy of histology assessment and accelerate drug development. PathAI's platform leverages advanced artificial intelligence to analyze and interpret pathology images, providing valuable insights to pathologists, researchers, and pharmaceutical companies. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com and follow us on LinkedIn. About University Hospital Zurich The University Hospital Zurich (USZ) is one of Europe's leading academic medical centers, offering cutting-edge clinical care and internationally recognized diagnostic expertise. The Department of Pathology and Molecular Pathology is a pioneer in digital and molecular pathology innovation. For more information, please visit www.usz.ch. [1] AISight Dx is CE-IVD-marked for primary diagnosis in the EEA, CH, and UK. [2] AIM-TumorCellularity is an AISight Dx workflow tool and not intended to be used for diagnostic purposes. [3] Smits et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Modern Pathology (2014) 27, 168 - 174.
PathAI and Northwestern Medicine have announced a multi-year collaboration to implement the AISight digital pathology platform and jointly develop artificial intelligence tools aimed at improving diagnostic accuracy and workflow in pathology.